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ABSTRACT
Cellular micro(mi)RNAs are able to recognize viral
RNAs through imperfect micro-homologies. Similar
to the miRNA-mediated repression of cellular trans-
lation, this recognition is thought to tether the RNAi
machinery, in particular Argonaute 2 (AGO2) on
viral messengers and eventually to modulate virus
replication. Here, we unveil another pathway by
which AGO2 can interact with retroviral mRNAs.
We show that AGO2 interacts with the retroviral
Group Specific Antigen (GAG) core proteins and
preferentially binds unspliced RNAs through the
RNA packaging sequences without affecting RNA
stability or eliciting translation repression. Using
RNAi experiments, we provide evidences that
these interactions, observed with both the human
immunodeficiency virus 1 (HIV-1) and the primate
foamy virus 1 (PFV-1), are required for retroviral rep-
lication. Taken together, our results place AGO2 at
the core of the retroviral life cycle and reveal original
AGO2 functions that are not related to miRNAs and
translation repression.
INTRODUCTION
Viruses are obligatory intracellular parasites that hijack
many, if not all, cellular pathways. The RNA interference
(RNAi) and micro (mi)RNA pathway is no exception
(1–3). The miRNAs control translation and protein
production by redirecting the miRNA ribonucleoprotein
(miRNP) complex (also called RNA-induced silencing
complex, RISC) on mRNAs harboring imperfect micro-
homologies (4,5). Though the complete composition
of the miRNP is not fully characterized, several key
effectors have been identiﬁed, such as the Argonaute
(AGO) proteins, DCP1 and GW182 proteins (4–6).
Mammalian genomes encode four AGOs that play redun-
dant roles in miRNA-mediated repression (7). In contrast,
AGO2 is the only AGO that functions in RNA interfer-
ence because its P-element induced wimpy testis (PIWI)
domain permits the cleavage of the mRNA at the center of
the siRNA–mRNA duplex (8). The AGO proteins, as well
as miRNAs, other component of the miRNP and miRNA
targets, are found in Processing (P)-bodies (9,10), cyto-
plasmic foci that are enriched in mRNA-catabolizing
enzymes and translational repressors (9). However,
AGO proteins can repress translation in the absence of
P-bodies, and P-bodies are formed as a consequence of
AGO function (11). In addition, AGO2 is also detected
with diffuse cytoplasmic staining (7). Hence, the exact im-
plication of P-bodies in RNA silencing and their import-
ance in AGO function(s) are not yet fully understood.
One aspect of the interplay between viruses and the
RNAi pathway is the capacity of host miRNAs to recog-
nize viral mRNAs (12–21). This recognition is detrimental
for several viruses (12,15–22) but beneﬁcial for Hepatitis C
Virus (HCV) (14,16). Moreover, the replication of certain
viruses is not at all affected by cellular miRNAs (15).
Hence, the link between viral RNAs and the host
miRNA machinery may rely on more complex mechan-
isms that remain to be clariﬁed (1,2,23).
To this aim, we dissected the interactions between the
host miRNA machinery and two unrelated retroviruses:
primate foamy virus 1 (PFV-1) (12) and human immuno-
deﬁciency virus 1 (HIV-1) (17–19,22). These two viruses
were studied because they represent the most distantly
related retroviruses and common features are likely to
be conserved in the whole Retroviridae family (24–26).
We show that AGO2 is also tethered on retroviral
RNAs through GAG and the GAG-interacting RNA
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translation repression. Using RNAi experiments, we
further revealed that AGO2, as opposed to other AGOs,
plays crucial functions in both PFV-1 and HIV-1 replica-
tions, a scenario akin to HCV (27,28). Together, our
results unveil original AGO2 functions that are unlinked
to miRNA and translation regulation, but yet hijacked by
both PFV-1 and HIV-1.
MATERIALS AND METHODS
Cells, viruses and transfection
293T cells were maintained in DMEM (Gibco-BRL) sup-
plemented with 2mM L-glutamine, 100mg/ml penicillin,
50mg/ml streptomycin and 10% fetal calf serum and trans-
fected with Lipofectamine 2000 (Invitrogen). Jurkat cells
were maintained in RPMI (Gibco-BRL) supplemented
with 2mM L-glutamine, 100mg/ml penicillin, 50mg/ml
streptomycin and 10% fetal calf serum and transfected
using the Amaxa Cell line Nucleofector kit V (Lonza).
Cell culture was realized using a Z1 Coulter Particle
counter (Beckman Coulter). To produce PFV-1 viruses,
293T were transfected with the pc13 provirus and,
2 days post-transfection, cells and supernatants were
collected and lysed by three successive cycles at
 80 C/37 C. The virus stock was collected after centrifu-
gation for 15min at 12000rpm and 4 C. To produce
HIV-1 virions, 293T cells were transfected with the
pNL4.3 provirus and supernatants were collected and
cleared using 0.45m ﬁlters.
Plasmids and mutagenesis
The following vectors were previously described:
myc-AGO2 and myc-PAZ9 in (22,29), pc13 in ref. (12),
pMH29 and pcgp1 in ref. (30), pFH-AGO2, pFH-
AG02-Y529A, pFH-AG02-Y52E, pFH-AG02-Y529F in
ref. (31), APOBEC3G-V5 in ref. (32). The pDCP1-ﬂag,
pAGO2-EGFP and pGW182-EGFP were provided by
W. Filipowicz. The pRFP-p54 was provided by D. Weil.
To construct EGFP-GAG vectors, the PFV-1 GAG ORF
was PCR-ampliﬁed and cloned into the SacII/XmaI re-
striction sites of pEGFP-C1. The GRI motif was deleted
using the QuickChange Mutagenesis kit (Stratagene) and
the primers are indicated in Supplementary Data. The
PFV-1 encapsidation sequences were ampliﬁed from the
pMH29 vector (provided by A. Rethwilm) (30). The PCR
product was inserted into the XhoI/NotI restriction sites
of the psiCHECK2 vector (Promega). The HIV-1 encap-
sidation sequence was extracted from pLK0-1 using BglII
and NotI. This sequence was further cloned in the XhoI
site of the psiCHECK2 vector. The sequences of the
siRNAs are indicated in Supplementary Data.
RNA-immunoprecipitations
The 293T cells were lysed 48 hpt (hours post-transfection)
in 20mM HEPES pH 7.5, 150mM NaCl, 2.5mM MgCl2,
250mM Sucrose, 0.05% NP40, 0.5% Triton X-100,
complete EDTA-free protease inhibitor cocktail (Roche).
Lysates were pre-cleared on Ig-G/sepharose beads for 1h
at 4 C and incubated overnight with the indicated
antibody ﬁxed on Ig-G/sepharose beads. After washes,
samples were treated with proteinase-K for 1h at 37 C
and immunoprecipitated RNAs were extracted using
Tri-Reagent (Invitrogen).
Quantitative RT–PCR
Total RNA was extracted using Tri-Reagent (Invitrogen).
We performed a DNase RQ1 (Sigma) treatment for 30min
at 37 Co n2 mg of RNA to digest residual genomic
DNA. RT was performed using the SuperScript II RT
(Invitrogen) and oligodT(N). qPCRs were performed
using SYBR Green PCR Master Mix (Roche). Primer se-
quences are indicated in Supplementary Data. Results are
means of at least three independent experiments.
Protein immunoprecipitation
Cells were lysed in 50mM Tris–HCl (pH 7.4), 100mM
NaCl, 5mM MgCl2, 1% Triton X-100, 0.5% sodium
deoxycholate, 0.05% sodium dodecyl sulfate (SDS),
complete EDTA-free protease inhibitor cocktail (Roche)
for 15min at 4 C. Lysates were pre-cleared on Ig-G/
sepharose beads and incubated overnight with speciﬁc
antibody ﬁxed on Ig-G/sepharose beads. Beads directly
coupled to anti-GFP antibodies (ChromoTek GmbH)
were also used. After washes, beads were heat-disrupted
at 100 C for 5min in Laemmli buffer. When indicated,
RNases A+T1 (Ambion) were added to the cell lysates
before immunoprecipitation (IP). The IP fractions or
 50mg of Laemmli total protein extracts were resolved
by SDS–PAGE and transferred onto a Nitrocellulose
Membrane (Protran Whatman Schleicher and Schuell).
Blots were incubated in 20mM Tris–HCl (pH 8),
150mM NaCl, 0.1% Tween-20 and 5% milk and further
incubated with speciﬁc antibodies diluted in the same
buffer. Western blots were revealed using an enhanced
chemiluminescence kit (Amersham).
Luciferase assays
The psiCHECK-2 Vector (Promega) contains a reporter
gene, ﬁreﬂy luciferase, which allows normalization of the
Renilla luciferase expression. This vector was transfected
in 293T cells, which were lysed in Passive Lysis Buffer
(Promega) 48 hpt. The expression of the Renilla and the
ﬁreﬂy luciferases were measured with the Dual-Luciferase
Reporter Assay System (Promega). Results are the mean
of at least three independent experiments (three biological
replicates and for each biological replicate (i.e. same
lysate), three technical replicates).
Antibodies
The antibodies used were: anti-myc (clone 9E10, Roche),
anti-V5 (Invitrogen), anti EGFP-HRP (MACS), anti-
Tubulin (Seotec), anti-Flag M2 (Sigma) and anti-HIV-1
p24 (AIDS reagent). Anti-AGO1 and anti-AGO2
antibodies were provided by G. Meister. The polyclonal
anti-PFV-1 antibodies were provided by A. Saı¨b. The
anti-p24 ELISA kit was purchased from Innogenetics.
776 Nucleic Acids Research, 2012,Vol. 40,No. 2Virion puriﬁcation
Retroviral particles were puriﬁed from cell culture
supernatants, which were cleared with 0.45m ﬁlter and
centrifuged through a 20% sucrose cushion in a solution
containing 100mM NaCl, 10mM Tris–HCl (pH 7.4), and
1mM EDTA at 25000rpm for 3h in a SW28 rotor
(Beckman) at 4 C.
Electron microscopy
Cells were ﬁxed in 2.5% glutaraldehyde, Sorensen buffer
(0.1M, pH 7.4) overnight at 4 C. Next day, cells were
washed in Sorensen’s buffer and post-ﬁxed in 1% osmic
acid for 1h at room temperature, then washed twice with
Sorensen’s buffer, dehydrated in a graded series of
ethanol, and embedded in epon resin. Sections were cut
with a Leica–Reichert Ultracut E and collected at different
levels of each block. The sections were counterstained with
uranyl acetate 1.5% in ethanol 70%, and observed using a
Hitachi 7100 transmission electron microscope equipped
with an AMT digital camera at ‘The Centre de Ressources
en Imagerie Cellulaire’ in Montpellier.
Yeast two-hybrid
The HIV-1 GAG and hAGO2 cDNAs were recovered
from donor vectors of the Gateway cloning system
(Invitrogen) and cloned into two-hybrid plasmids
(pACT-II and pAS2). For the two-hybrid assays,
plasmids were introduced into the appropriate haploid
strains (CG929 or YL455), which were then crossed.
Diploids were plated on double or triple selectable
media (minus Leu, Trp, or minus Leu, Trp, His), and
growth was assessed 3 days later. We used Alix as a
positive control for the interaction with HIV-1 GAG
(33) and Rsa (a yeast protein) as negative control.
RESULTS
The PFV-1 and HIV-1 mRNAs can interact with the
RNAi machinery in a miRNA- and
P-body-independent manner
In order to conﬁrm the interactions of PFV-1 RNAs with
the RNAi machinery (12), we ﬁrst performed
RNA-immunoprecipitations (RNA-IPs) in 293T cells
transfected with the PFV-1 provirus and myc-AGO2 or
DCP1-ﬂag vectors. These experiments indeed showed that
PFV-1 RNAs co-immunoprecipitated with both AGO2
and DCP1 (Figure 1A). Strikingly, using a different set
of primers, we further observed that AGO2 preferentially
bound unspliced PFV-1 RNAs (Figure 1B). The spliced
RNA form was below PCR detection limit (Figure 1B).
Because the interaction between PFV-1 RNAs and
miRNAs seemed to differ from that usually observed in
the case of cellular mRNAs, we evaluated the role of host
miRNAs in the interactions depicted in Figure 1A. We
used a mutant of AGO2 that is unable to interact with
miRNAs (called PAZ9) (29,31). PAZ9 is not detectable in
P-bodies although it is still able to interact with DCP1
[(29) and data not shown] and to induce RNA silencing
when artiﬁcially tethered to RNA (31). We observed that
PFV-1 RNAs also co-immunoprecipitated with PAZ9,
suggesting that the interaction between PFV-1 RNAs
and AGO2 does not strictly require miRNAs and occurs
outside of P-bodies (Figure 1A).
We then repeated these experiments with HIV-1 for
which key interactions with miRNAs have also been
documented (17–19). We performed anti-myc RNA-IPs
in 293T cells transfected with the HIV-1 pNL4.3
provirus and myc-AGO2 or myc-PAZ9 expressing
vectors. We found that both AGO2 and PAZ9 interacted
with spliced and unspliced HIV-1 RNAs although to dif-
ferent extents (Figure 1C): 30% of unspliced RNAs inter-
acted with AGO2 independently of miRNAs (Figure 1C,
compare IP AGO2 with IP PAZ9), while the vast majority
(98%) of the spliced RNAs interacted with AGO2 in a
miRNA-dependent manner (Figure 1C). We concluded
that host miRNAs and P-bodies are not strictly required
for the interaction between unspliced retroviral RNAs and
AGO2. Since unspliced RNAs can be speciﬁcally packed
into virus-derived ribonucleoprotein complexes en route
to virion egress, we hypothesized that viral proteins
could also interact with core components of the RNAi
machinery.
The PFV-1 and HIV-1 GAG proteins interact with
AGO2 in a miRNA- and P-body-independent manner
To test this idea, 293T cells were transfected with the
PFV-1 provirus and myc-AGO2 expressing vector.
Using immunoprecipitation experiments, we observed
that PFV-1 GAG co-immunoprecipitated with myc-
AGO2 and that, inversely, myc-AGO2 co-immuno-
precipitated with PFV-1 GAG (Figure 2A).
Interestingly, the GAG:AGO2 interaction was insensitive
to RNase treatment (Figure 2A), suggesting that RNAs,
in particular viral RNAs, were not required. In fact, when
expressed alone in 293T cells, in the absence of a viral
genome, PFV-1 GAG co-immunoprecipitated with
myc-AGO2 (Figure 2B). We also observed that PAZ9
co-immunoprecipitated with PFV-1 GAG (Figure 2B)
indicating that the GAG:AGO2 interaction did not neces-
sitate miRNAs or P-bodies. To conﬁrm that RNAs were
not required for the GAG:AGO2 interaction, we mutated
the nucleic acid binding domain of PFV-1 GAG (34) and
veriﬁed that this mutant was still able to co-immuno-
precipitate with myc-AGO2 (Figure 2C). We also
veriﬁed that PFV-1 GAG interacted with endogenous
AGO1 and AGO2 (Figure 2D).
Similarly, we found that the HIV-1 GAG precursor
Pr55 interacted with tagged DCP1 and AGO2, independ-
ently of RNAs, miRNAs and P-bodies, in infected Jurkat
T-cells (Figure 3A) as well as in transfected 293T cells
(Figure 3B). In agreement with these observations, we
also showed that HIV-1 Pr55 GAG interacted with differ-
ent AGO2 mutants (Figure 3C), which exhibit distinct
miRNA binding capacities and P-body localization (31),
in 293T* cells stably expressing only HIV-1 GAG and
POL (35,36). The HIV-1 GAG also co-immuno-
precipitated with endogenous AGO1 and AGO2 in
293T* cells (Figure 3D). We did not, however, detect
any interaction between HIV-1 GAG and AGO2 using
Nucleic AcidsResearch, 2012, Vol.40,No. 2 777yeast two-hybrid assays suggesting that this interaction is
indirect and requires additional cellular co-factors (data
not shown).
Retroviral GAG proteins elicit the recognition of viral
mRNAs by AGO2 but do not trigger RNA silencing
Since GAG proteins bind viral RNAs through the encap-
sidation signals spanning intronic sequences (30,37),
we hypothesized that GAG could recruit the RNAi ma-
chinery (notably DCP1 and AGO2) to viral RNAs
through RNA packaging sequences. We indeed observed
that the amount of PFV-1 RNAs interacting with DCP1
paralleled the expression of the cognate GAG protein
(Supplementary Figure S1). Thus, to directly test the po-
tential involvement of the RNA packaging signals, we
constructed a Renilla luciferase reporter containing
the PFV-1 encapsidation sequences (30) (Figure 4A).
This reporter was transfected into 293T cells together
with the myc-AGO2 expression vector. Anti-myc immuno-
precipitations followed by RT–PCR amplifying the Renilla
mRNA showed that AGO2 alone was not able to interact
with the reporter RNA (Figure 4A). In contrast, in the
presence of PFV-1 GAG, AGO2 bound the Renilla
reporter containing the PFV-1 packaging signals
(Figure 4A). As controls, we repeated these experiments
with a Renilla reporter devoid of encapsidation sequences
or a reporter containing the HIV-1 packaging signal. We
observed that AGO2 did not bind these reporter RNAs,
even in the presence of PFV-1 GAG (Figure 4A).
Similarly, we did not detect a signiﬁcant enrichment of
GAPDH mRNA in the IP fractions (Figure 4A). These
results indicated that PFV-1 GAG speciﬁcally elicited the
recognition of PFV-1 mRNAs by AGO2 through
packaging sequences. We then repeated these experiments
with HIV-1 packaging signals. Similarly, we observed that
Figure 1. Retroviral mRNAs interact with the RNAi machinery independently of miRNAs and P-bodies. (A) 293T cells were transfected with the
PFV-1 pc13 provirus together with vectors encoding myc-AGO2/myc-PAZ9 (left) or DCP1-ﬂag (right). IPs directed against the myc tag (left) or the
ﬂag tag (right) were performed 48 hpt. IP (pellet) and cell-extract (input) RNAs were further analyzed by RT–PCR. IP efﬁciency was controlled by
western blots (WBs). (B) IP RNAs described in (A) were analyzed by RT–PCR using primers discriminating spliced (S) and unspliced (U) RNAs.
RNase treatment was performed before IP to assess potential DNA contamination (due to DNA transfection). (C) 293T cells were transfected with
the HIV-1 pNL4.3 provirus and the myc-AGO2 or myc-PAZ9 expression vectors. IPs directed against the myc tag were performed 48 hpt. RNAs
were extracted from immunoprecipitated fractions and assayed for the presence of spliced (black) and unspliced (gray) viral RNAs by RT–qPCR.
The log(fold enrichment, FE)={log[2
^(Ct noAb – Ct IP)]} was calculated. The log representation was chosen in order to underscore the FE obtained
with spliced RNAs bound to PAZ9. The details of our calculation are shown.
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HIV-1 packaging signals in the presence of HIV-1 GAG
(Figure 4D). We veriﬁed that HIV-1 GAG was not able to
recruit AGO2 to the Renilla reporter containing the
PFV-1 encapsidation sequences (Figure 4D). Together
with the results shown in Figure 4A, this result indicated
that the recruitment of AGO2 through GAG requires the
cognate RNA packaging sequences.
We then assessed the effect of the GAG-recruited
AGO2 on RNA stability and translation using the report-
ers described in Figure 4A and D. We observed that
tethering AGO2 to these reporters via GAG did not
inhibit translation (Figure 4B and E) nor affect RNA sta-
bility (Figure 4C and F). Accordingly, the expression of
PFV-1 GAG did not affect siRNA-triggered RNA inter-
ference directed against the luciferase (Supplementary
Figure S2). Hence, we concluded that retroviral GAG
hijacked AGO2 functions that are not related to RNA
silencing and miRNAs.
AGO2 is encapsidated in retroviral particles
We showed PFV-1 and HIV-1 GAGs speciﬁcally elicited
the recognition of viral mRNAs by AGO2 through RNA
Figure 2. PFV-1 GAG interacts with AGO2 independently of miRNAs and P-bodies. (A) 293T cells were transfected with pc13 and myc-AGO2
vectors. IPs anti-PFV-1 proteins or anti-myc were performed 48 hpt. IP (pellet) and cell lysates (input) were analyzed by WB as indicated. RNase
treatment was carried out before IP. (B) 293T cells were transfected with PFV-1 EGFP-GAG and myc-AGO2, myc-PAZ9 or pcDNA3 (mock)
vectors. Anti-myc or anti-HA (used as a negative control), IPs were performed 48 hpt. WBs were also performed as indicated. The WB signals were
further quantiﬁed and the enrichment of co-immunoprecipitated PFV-1 GAG was calculated in each case using the following formula: [(GAG signal
in pellet /GAG signal in input)/ AGO2/PAZ9 signal in pellet] 100. (C) PFV-1 GAG mutated in the GRI domain, which is involved in nucleic acid
interaction, was constructed in the pcgp1 background (GAGGRI). 293T cells were transfected with the mutated PFV-1 GAG and the myc-AGO2
expression vectors. Anti-myc IPs were performed 48 hpt. Anti-PFV-1 WBs were performed on immunoprecipitated fractions (pellet) and cell extracts
(input). An anti-myc WB was also performed to control IP efﬁciency (bottom). (D) 293T cells were transfected with PFV-1 EGFP-GAG. IPs directed
against EGFP-GFP were performed 48 hpt. Immunoprecipitated fractions (pellet) and cell lysates (input) were analyzed by WB as indicated.
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presumed that AGO2 was encapsidated in retroviral
particles. To test this idea, we puriﬁed PFV-1 virions
produced from 293T cells transfected with the
PFV-1 provirus and vectors expressing AGO2-myc or
APOBEC3G-V5 (hA3G-V5), used as a positive control
(38,39). Both AGO2-myc and APOBEC3G-V5 proteins
were detected in PFV-1 particles, whereas no protein
was detectable in the supernatant of uninfected cells
(Figure 5A). The AGO2 mutant PAZ9 was similarly
encapsidated (Figure 5A), suggesting that the encapsida-
tion of AGO2 occurs in a manner independent of P-bodies
and miRNAs. In similar settings, we failed to detect
GW182-EGFP in PFV-1 particles (Figure 5B). We also
tested whether HIV-1 particles likewise encapsidated
AGO2. For this purpose, 293T* cells expressing HIV-1
GAG-POL (35,36) and unmodiﬁed 293T cells (used as
negative control) were transfected with the PAZ9-myc
vector (Figure 5C). The PAZ9-myc protein was only
detected in the supernatant of 293T* (Figure 5C),
indicating that HIV-1 virus-like particles (VLPs) are able
to encapsidate AGO2 independently of miRNAs and
P-bodies. These results were consistent with the inter-
action existing between AGO2 and the HIV-1 Pr55
GAG precursor (Figure 3), whose maturation occurs
after viral budding (40). As observed in the case of
PFV-1, the GW182-EGFP protein was not detected in
HIV-1 VLPs (Figure 5D), indicating that not all
miRNA-related proteins are packed in retroviral particles.
AGO2 is required for retroviral replication
We next questioned the functional consequences of
GAG-mediated AGO2 recruitment. We silenced AGO2,
Figure 3. HIV-1 GAG interacts with AGO2 independently of miRNAs and P-bodies. (A) Jurkat cells were transfected with myc-AGO2 or
DCP1-ﬂag vectors and further infected with HIV-1. Anti-myc or anti-ﬂag IPs were performed 48 hpt. IP fractions (pellet) or cell lysates (input)
were analyzed by WBs. (B) Similar experiments were conducted in 293T cells transfected with pNL4.3 and myc-AGO2 or myc-PAZ9 vectors. RNase
treatment was performed as described in Figure 2A. The WB signals were further quantiﬁed and the enrichment of co-immunoprecipitated HIV-1
GAG was calculated in each case using the following formula: [(GAG signal in pellet/GAG signal in input)/ AGO2/PAZ9 signal in pellet] 100.
(C) 293T* cells were transfected with Flag/HA-tagged versions of AGO2 wild-type (FH-AGO-WT) or mutated at position 529 (Y529A, Y529E and
Y529F). Anti-ﬂag IPs were performed 48 hpt. WBs were executed as indicated on IP fractions (pellet) or cell lysates (input). (D) IPs directed against
endogenous AGO1 and AGO2 were performed in 293T* cells. WBs were executed as indicated on IP fractions (pellet) or cell lysates (input).
780 Nucleic Acids Research, 2012,Vol. 40,No. 2Figure 4. The retrovirus core GAG protein recruits AGO2 on viral RNAs without eliciting RNA silencing. (A) 293T cells were transfected with the
empty psiCHECK2 vector or a psiCHECK2 containing the encapsidation sequences of PFV-1 (PFV-1 c), as well as myc-AGO2 and PFV-1 GAG
expressing vectors as indicated. IPs directed against the myc tag were performed 48 hpt. RNAs extracted from IP fractions were assayed for the
presence of the Renilla RNA by RT–qPCR. Fold enrichment was calculated using the following formula: 2^(Ct input-Ct IP) – (Ct input obtained in
the no Ab condition – Ct IP obtained in the no Ab condition). As control, a reporter containing the HIV-1 encapsidation sequences (psiCHECK2
HIV-1 c) was also tested. The RNAs extracted from myc-AGO2 IPs in the presence or absence of PFV-1 GAG were also assayed for the presence of
the GAPDH mRNA by RT–qPCR. Surprisingly, although several miRNAs are predicted to target the GAPDH mRNA (according to miRBase,
http://www.mirbase.org/), no RNA enrichment was observed in the myc-AGO2 IP fraction. Anti-myc WBs were also performed to control IP
efﬁciency (bottom, one representative example is shown). (B) 293T cells were transfected with the psiCHECK2 vector or PFV-1 c and increasing
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(continued)Figure 4. Continued
amount of PFV-1 GAG. Dual-luciferase assays were performed 48 hpt. The results were normalized with the values obtained with each construct in
the absence of GAG (Renilla/Fireﬂy ratio or Renilla/Fireﬂy ratio obtained in the absence of GAG). (C) 293T cells were transfected as in (B) and RT–
qPCRs directed against Renilla and Fireﬂy luciferases were performed 48 hpt. The ratio Renilla/Fireﬂy was calculated and the values obtained in the
absence of GAG were used as reference. (D) 293T cells (devoid of HIV-1 GAG) and 293T* cells (stably expressing HIV-1 GAG-POL) were
transfected with the empty psiCHECK2 vector or a psiCHECK2 containing the encapsidation sequences of HIV-1 (HIV-1 c) as well as
myc-AGO2 as indicated. As control, the reporter described in (A) was also tested. IPs directed against the myc tag were realized 48 hpt. RNAs
extracted from immunoprecipitated fractions were assayed for the presence of the renilla RNA by RT–qPCR. Anti-myc WBs were also performed to
control IP efﬁciency (bottom, one representative example is shown). (E) 293T and 293T* cells were transfected with the psiCHECK2 vector or the
HIV-1 c and Dual-luciferase assays were performed 48 hpt. The results were normalized with the values obtained with each construct in the absence
of GAG (Renilla/Fireﬂy ratio or Renilla/Fireﬂy ratio obtained in the absence of GAG). (F) 293T and 293T* cells were transfected with the
psiCHECK2 vector or the HIV-1 c and RT–qPCRs were performed 48 hpt as in (C).
Figure 5. AGO2 is encapsidated in retroviral particles. (A) 293T cells were transfected with the PFV-1 provirus and hA3G-V5, myc-AGO2 or
myc-PAZ9 vector. hA3G-V5 was used as a positive control (38,39). PFV-1 virions were puriﬁed on a 20% sucrose cushion 48 hpt and assayed for the
presence of myc-AGO2/PAZ9 and hA3G-V5 by WBs. (B) The experiments described in (A) were repeated except that 293T cells were transfected
with the PFV-1 provirus and a GW182-EGFP vector. (C) 293T* and 293T cells were transfected with the myc-PAZ9 expression vector. The culture
supernatants were puriﬁed on a sucrose cushion 48 hpt and assayed for the presence of myc-PAZ9 by WB. (D) The experiments described in (C) were
repeated using a GW182-EGFP vector.
782 Nucleic Acids Research, 2012,Vol. 40,No. 2as well as AGO1, AGO3, AGO4, GW182 and p54/RCK
(also known as DEAD (Asp-Glu-Ala-Asp) box
polypeptide 6, DDX6) (Supplementary Figure S3) and
measured HIV-1 particle production in Jurkat T-cells
(Figure 6A). We observed that siRNAs directed against
AGO2 and AGO3 signiﬁcantly decreased HIV-1 particle
production (Figure 6A). Conversely, RNAi directed
against GW182 increased viral replication (Figure 6A),
as previously reported (19,22). It is noteworthy that
siRNAs anti-AGO2 and anti-AGO3 did not synergize to
limit HIV-1 replication (Figure 6A). These experiments
suggested that AGO2, and possibly AGO3 (41), as
opposed to AGO1 and AGO4, play positive functions in
HIV-1 replication. Next, we asked whether AGO2 could
directly impact retroviral capsid formation and measured
HIV-1 VLP formation in 293T* cells (35,36) transfected
with siRNAs directed against several RNAi components
(Figure 6B). We observed that anti-AGO2 siRNAs signiﬁ-
cantly decreased VLP formation compared with other
siRNAs (Figure 6B), revealing positive functions of
AGO2 in HIV-1 capsid assembly. Of note, AGO3
siRNAs, on the other hand, decreased HIV-1 replication
[Figure 5A and (41)] but did not affect VLP formation
(Figure 6B). Conversely, AGO1 was not signiﬁcantly
implicated in HIV-1 virion production (Figure 6A) but
anti-AGO1 RNAi affected VLP production (Figure 6B).
These results might be indicative of AGO3 and AGO1
cellular functions that might indirectly impact replication
and capsid formation respectively. Using electron micros-
copy, we further examined HIV-1 VLPs in 293T* cells
transfected with siRNAs directed against AGO2 or, as a
control, p54/RCK (Figure 6C). These analyses showed
that, upon AGO2 RNAi, HIV-1 VLPs were retained in
the cytoplasm and were smaller and less dense, compared
to VLPs observed upon p54/RCK RNAi (Figure 6C).
Together these observations conﬁrmed that AGO2 is
required for HIV-1 replication, in particular for the
assembly of viral particles.
Similar experiments were also performed in the case of
PFV-1. In contrast to orthoretroviruses, PFV-1 GAG
proteins expressed on their own do not form VLPs (42).
The replication of PFV-1 was measured as described in
ref. (12). While RNAi anti-AGO1, -AGO3, -AGO4,
-GW182 or -p54/RCK did not signiﬁcantly impair
PFV-1 replication in 293T cells, siRNAs directed against
AGO2 consistently diminished virus production (Figure
6D). Hence, in accordance with our initial hypothesis,
AGO2, as opposed to other AGOs, seems to play
positive functions in both PFV-1 and HIV-1 replications,
a scenario akin to HCV (27,28).
DISCUSSION
Here, we show that retroviral GAG and the
GAG-interacting RNA packaging signals can recruit
AGO2 onto RNA without eliciting translation repression.
However, our results also conﬁrm an important contribu-
tion of host miRNAs in the interaction of AGO2 with
retroviral RNAs (12,17–19,22). In fact, the majority of
HIV-1 RNAs requires host miRNAs to interact with
AGO2: 70% of unspliced and 98% of spliced HIV-1
RNAs interact with AGO2 in a miRNA-dependent
manner (Figure 1C). Thus, we can now distinguish at
least two ways to recruit AGO2 on retroviral
mRNAs: one elicited by host miRNAs (12,17–19,22) and
a second, mediated by GAG and the RNA packaging se-
quences. These two types of interaction are not exclusive
and are probably implicated in distinct steps of the retro-
viral life cycle. As viruses have co-evolved with the
miRNA repertoire of their hosts (14,17,43,44), the ﬁrst
mode, that is dependent on host miRNAs, could have
an impact on retroviral replication: for instance, at a par-
ticular time point [e.g. latent infection (17)], in speciﬁc cells
[e.g. resting cells (17)] and/or with certain RNAs (e.g.
spliced RNAs, Figure 1C). On the other hand, mRNA
recognition by miRNAs [Figure 1 and (12,18,19,22,45)],
interaction with other RNAi proteins [such as DCP1
(Figures 1A and 3A) or AGO1 (Figures 2D and 3C)]
and sequestration in P-bodies (19,22) could also represent
deleterious consequences of the recruitment of AGO2 or
other miRNA-related components on viral RNAs. PFV-1
and HIV-1 could have therefore developed protein- or
RNA-based strategies to limit the negative effects of
cellular miRNAs (12,46–49). Interestingly, host miRNAs
also play both beneﬁcial and detrimental roles in HCV
replication (13,14,16) and AGO2 was recently shown to
be required for efﬁcient HCV replication (27,28). Similar
to the retroviral GAG protein, the miR-122 recruits an
AGO2-containing complex onto viral mRNAs (27,28)
with unclear consequences: miR-122 is able to stimulate
HCV translation (50,51) but this effect is not sufﬁcient to
fully explain its actions on HCV replication (14,52).
Recently, and in accordance with our results, the replica-
tion of HCV RNA was shown to depend on recruitment
of AGO2 and miR-122 to lipid droplets, not P-bodies,
while suppression of HCV RNA by siRNA and AGO2
involves interaction with P-bodies (53). It has been
postulated that the miR-122 interaction with HCV RNA
changes during the viral life cycle (28), as hypothesized
here in the case of the interactions between retroviral
RNAs and AGO2. Hence, it is possible that HCV and
retroviruses similarly hijack some AGO2 functions that
are not related to translation regulation. Provided, the
considerable differences existing between Retroviridae
and Flaviviridae, it is tempting to speculate that these
AGO2 functions are also implicated in the replication of
other viruses. The experiments showing that vaccinia, in-
ﬂuenza A or encephalomyocarditis viruses are not affected
by the blockade of miRNA biogenesis (15) do not exclude
an authentic contribution of some RNAi-related proteins,
in particular AGO2, in their replication.
Taken together, our results shed a new light on the
cellular functions of AGO2 as it can be recruited onto
messenger RNAs without eliciting RNA silencing.
Our results support the idea that AGO2 has original func-
tions that are not related to miRNAs and RNA silencing
(54). In fact, AGO2 has previously been found in speciﬁc
protein complexes that are not linked to miRNA biogen-
esis or RNA interference (54). We anticipate that
these functions will be deciphered by further studies on
Nucleic AcidsResearch, 2012, Vol.40,No. 2 783Figure 6. AGO2 is required for HIV-1 and PFV-1 replication. (A) Jurkat cells were transfected with the HIV-1 provirus and indicated siRNAs. Viral
production was measured 48 hpt using anti-p24 ELISA assays. Results are the mean of at least three independent experiments. *P<0.01 (Student’s
test). (B) HIV-1 VLP production from 293T* cells was measured 48 hpt of the indicated siRNAs using anti-p24 ELISA assays. Results are the mean
of three independent experiments. *P<0.005 (Student’s test). (C) Electron microscopy of HIV-1 VLPs produced in 293T* transfected with siRNA
directed against AGO2 or p54/RCK, as a control. The size and the number of VLPs per cell are indicated in each condition. Arrows show VLPs.
Right panels are enlargements of squares indicated in left panels. (D) 293T cells were transfected with the PFV-1 provirus and indicated siRNAs
(T1). Separate cells were transfected with Fireﬂy luciferase driven by the PFV-1 Long Terminal Repeat (LTR), activated by the transactivator Tas
(T2). Supernatants of T1 were used to infect cells from T2. Luciferase expression was quantiﬁed in T2 cells. *P<0.005 (Student’s test).
784 Nucleic Acids Research, 2012,Vol. 40,No. 2the AGO2-containing complex(es) implicated in viral
replication.
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